LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

83.09

Resumen

Variación precio

24h

Actual

Mínimo

81.89

Máximo

83.31

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-254M

-103M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+16.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.4B

13B

Apertura anterior

83.09

Cierre anterior

83.09

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

290 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 feb 2026, 17:37 UTC

Adquisiciones, fusiones, absorciones

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

21 feb 2026, 14:31 UTC

Adquisiciones, fusiones, absorciones

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Ganancias

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Ganancias

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Charlas de Mercado

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Adquisiciones, fusiones, absorciones

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20 feb 2026, 20:17 UTC

Charlas de Mercado

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20 feb 2026, 20:11 UTC

Charlas de Mercado

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20 feb 2026, 19:59 UTC

Charlas de Mercado

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20 feb 2026, 19:58 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20 feb 2026, 19:49 UTC

Charlas de Mercado

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20 feb 2026, 19:09 UTC

Charlas de Mercado

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20 feb 2026, 19:00 UTC

Charlas de Mercado

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20 feb 2026, 18:28 UTC

Charlas de Mercado

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20 feb 2026, 18:20 UTC

Charlas de Mercado

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20 feb 2026, 18:05 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 18:04 UTC

Charlas de Mercado

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20 feb 2026, 17:38 UTC

Charlas de Mercado

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Correction to Treasury Yields Fall Market Talk

20 feb 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

20 feb 2026, 16:53 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 16:53 UTC

Charlas de Mercado

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

16.92% repunte

Estimación a 12 meses

Media 97.22 USD  16.92%

Máximo 110 USD

Mínimo 87 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

290 / 351 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat